News & Events

CAMBRIDGE, Mass., Feb 29, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that the Company will participate in an HCV panel, entitled: "HCV: Protease Inhibitors and Beyond" at Susquehanna Financial Group's Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5, 2008 from 8:15 a.m. to 9:15 a.m. EST. An archive of the presentation will be webcast by Susquehanna immediately following conclusion of the HCV panel.

The presentation will be recorded and the replay will be webcast for two weeks following the panel. The webcast may be accessed from the 'Events & Presentations' page of Vertex's website at www.vrtx.com.

About Vertex

Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, inflammation, autoimmune diseases, cancer, pain and bacterial infection. Vertex co-discovered the HIV protease inhibitor, Lexiva, with GlaxoSmithKline.

Lexiva is a registered trademark of the GlaxoSmithKline group of companies.

Vertex's press releases are available at www.vrtx.com.

(VRTX-WEB)

SOURCE: Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated
Lora Pike, 617-444-6755
Manager, Investor Relations

Copyright Business Wire 2008

News Provided by COMTEX